Trademark search for:

SIMLANDI (ADALIMUMAB-XXXX) INJECTION

EXPIRED USPTO USPTO

USPTO

No active United States Patent and Trademark Office (USPTO) registrations found, based on publicly available USPTO trademark records.

Trademark records may change over time. For the most up-to-date trademark status, domain availability, and social handle checks, run a live search.

Live search · Most up-to-date results

Also check across:

USPTO Filing History

Key events recorded for this trademark application

2021-08-12 — Application filed
2021-08-16 — Application filed
2021-10-04 — Application filed
2021-10-05 — Notice of design search code e-mailed
2021-11-12 — Assigned to examiner
2021-11-18 — Approved for pub - principal register
2021-11-18 — Examiner's amendment entered
2021-11-18 — Examiners amendment e-mailed
2021-11-18 — Notification of examiners amendment e-mailed
2021-11-18 — Examiners amendment -written
2021-11-30 — Withdrawn from pub - og review query
2021-12-07 — Previous allowance count withdrawn
2021-12-08 — Approved for pub - principal register
2021-12-10 — Assigned to lie
2021-12-11 — Law office publication review completed
2021-12-29 — Notification of notice of publication e-mailed
2022-01-18 — Published for opposition
2022-01-18 — Official gazette publication confirmation e-mailed
2022-03-15 — Noa e-mailed - sou required from applicant
2022-09-15 — Sou extension 1 filed
2022-09-15 — Sou teas extension received
2022-09-15 — Sou extension 1 granted
2022-09-17 — Notice of approval of extension request e-mailed
2023-03-06 — Sou extension 2 filed
2023-03-06 — Sou teas extension received
2023-03-06 — Sou extension 2 granted
2023-03-08 — Notice of approval of extension request e-mailed
2023-09-12 — Sou teas extension received
2023-09-12 — Sou extension 3 filed
2023-09-12 — Sou extension 3 granted
2023-09-14 — Notice of approval of extension request e-mailed
2024-03-13 — Sou extension 4 filed
2024-03-13 — Sou teas extension received
2024-03-13 — Sou extension 4 granted
2024-03-14 — Notice of approval of extension request e-mailed
2024-08-30 — Use amendment filed
2024-08-30 — Teas statement of use received
2024-11-01 — Case assigned to intent to use paralegal
2024-11-01 — Statement of use processing complete
2024-11-04 — Final disposition recorded
2024-11-04 — Final disposition recorded
2024-11-04 — Final disposition recorded
2025-02-21 — Application abandoned
2025-02-21 — Application abandoned
2025-02-21 — Final status recorded

Owner Information

TEVA PHARMACEUTICALS USA, Inc.
Parsippany , NJ

TEVA PHARMACEUTICALS USA, Inc.
Parsippany , NJ

Correspondent

Laurence Rickles TEVA PHARMACEUTICALS USA, INC.
400 INTERPACE PARKWAY
BUILDING A
PARSIPPANY, NJ 07054

Filing Details

Filing Date:
2021-08-12

Status Date:
2025-02-21

Category:
Pharmaceuticals

Filing Year:
2021

Disclaimer: This page is informational only and does not constitute legal advice. Trademark availability depends on jurisdiction, usage, and legal interpretation.